Anthem Capital Management is an early stage venture firm that invests in companies in the mid-Atlantic states.
Business Model:
Revenue: $14.8M
Employees: 51-200
Address: 1414 Key Hwy
City: Baltimore
State: MD
Zip: 21230
Country: US
Anthem Capital Management is an early stage venture firm that invests in companies in the mid-Atlantic states. Anthem’s team has accumulated more than 50 years of venture capital experience. They were early venture investors in such companies as Apple Computer, Samna (Lotus’s word processor), Sequoia Software, HealthSouth, Phycor, Corporate Childcare Services, Immunicon and Sensors for Medicine and Sciences. Regional Footprint Anthem invests exclusively in the Mid-Atlantic states and serves this area from offices located in three of the region’s key markets: the Baltimore–Washington corridor, the Greater Philadelphia market, and the Greater Pittsburgh market. Industry Focus Anthem seeks opportunities in IT/telecom and healthcare/life sciences industries. IT investments are most frequently made in enterprise software or network management software companies. Medical investments tend to fall into three categories: medical devices, biotechnology or healthcare. Investment Stage Anthem invests in early to expansion stage opportunities. Typically, our initial investment is made in the Series A or Series B institutional venture capital round. We have led or co-led 80% of the investments we have made, but also will participate in syndicates where appropriate. Investment Size Anthem seeks to invest between $2 million and $4 million in a company from the first private equity round through exit. Typically, our initial investment ranges from $1 million to $2 million
Contact Phone:
+14106251510
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2003 | Qovia | Series A | 5.5M |
9/1999 | ScoreBoard | Series A | 4.2M |
7/2000 | ScoreBoard | Series B | 25M |
2/2003 | Siperian | Series B | 8.3M |
6/2000 | Highway To Health | Venture Round | 14.5M |
5/2003 | GlycoMimetics | Series A | 4.3M |
1/2008 | Siperian | Series E | 25M |
11/2007 | RedLasso | Series A | 6.9M |
6/2006 | Qovia | Series C | 0 |
6/2006 | GlycoMimetics | Series B | 0 |
6/2014 | Senseonics | Venture Round | 0 |
8/2004 | GlycoMimetics | Series A | 5.1M |
4/2004 | Qovia | Series B | 10.6M |
3/2007 | Defywire | Venture Round | 0 |
4/2005 | Defywire | Series B | 0 |
3/2004 | BioRexis | Series B | 30M |
6/2004 | Nucleonics | Series B | 49.2M |
6/2003 | Defywire | Series A | 4.5M |
1/1999 | Message Pharmaceuticals | Venture Round | 6.3M |
12/2009 | GlycoMimetics | Series C | 0 |
7/2005 | Immune Control | Series A | 0 |
10/2008 | Echo360 | Venture Round | 0 |
3/2006 | Triumfant | Series B | 0 |
6/2014 | Senseonics | Venture Round | 0 |
12/2009 | GlycoMimetics | Series C | 0 |
10/2008 | Echo360 | Venture Round | 0 |
1/2008 | Siperian | Series E | 0 |
11/2007 | RedLasso | Series A | 0 |
3/2007 | Defywire | Venture Round | 0 |
6/2006 | GlycoMimetics | Series B | 0 |
6/2006 | Qovia | Series C | 0 |
3/2006 | Triumfant | Series B | 0 |
7/2005 | Immune Control | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|